NuCana (NCNA) Projected to Post Earnings on Thursday

NuCana (NASDAQ:NCNA) is expected to announce its results before the market opens on Thursday, March 19th. Analysts expect the company to announce earnings of ($2.6944) per share for the quarter.

NuCana Trading Down 2.1%

Shares of NASDAQ NCNA opened at $1.86 on Wednesday. NuCana has a 12 month low of $1.85 and a 12 month high of $268.00. The stock has a 50 day moving average of $2.52 and a 200-day moving average of $3.47. The company has a market capitalization of $55,800.00, a P/E ratio of -0.01 and a beta of 1.69.

Analysts Set New Price Targets

A number of brokerages recently commented on NCNA. Wall Street Zen upgraded shares of NuCana from a “sell” rating to a “hold” rating in a research report on Saturday, November 22nd. Weiss Ratings reissued a “sell (e+)” rating on shares of NuCana in a research note on Thursday, January 22nd. One analyst has rated the stock with a Sell rating, According to MarketBeat.com, the stock has an average rating of “Sell”.

About NuCana

NuCana plc, headquartered in Edinburgh, Scotland, is a clinical-stage biopharmaceutical company focused on developing novel anti-cancer therapies. The company leverages its proprietary ProTide platform to deliver enhanced nucleoside analogues designed to overcome resistance mechanisms commonly encountered in standard chemotherapy regimens. NuCana’s research and development efforts are aimed at improving safety and efficacy profiles for patients with a range of solid tumor indications.

At the core of NuCana’s pipeline is NUC-3373, a next-generation fluoropyrimidine analogue engineered to bypass degradation pathways and achieve more consistent intracellular exposure.